American-Chinese, Google-backed AI drug discovery company XtalPi has expanded its collaboration agreement (previously entered in 2020) with US-based oncology drug discovery company Signet Therapeutics to include a new drug program. The terms and financial details of the collaboration have not been disclosed.
The new collaborative program will discover novel drug candidates against a novel cancer target identified by Signet, by leveraging XtalPi’s AI platform combined with Signet's unique novel organoid disease model platform.
The initial collaboration between the two parties resulted in the identification of novel preclinical candidates for a new gastric cancer target—in approximately six months—which are approaching clinical trials.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.